Provided by Tiger Trade Technology Pte. Ltd.

10x Genomics, Inc.

66.17
-1.1200-1.66%
Volume:237.32K
Turnover:15.52M
Market Cap:8.62B
PE:-112.46
High:66.50
Open:65.17
Low:64.03
Close:67.29
52wk High:67.62
52wk Low:11.16
Shares:130.29M
Float Shares:118.00M
Volume Ratio:1.04
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5884
EPS(LYR):-0.3490
ROE:-9.40%
ROA:-5.05%
PB:10.44
PE(LYR):-189.57

Loading ...

Nov 08, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 05, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Oct 30, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 29, 2024

Major Issues Report

Form 8-K - Current report
Oct 09, 2024

Major Issues Report

Form 8-K - Current report
Aug 22, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 22, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 22, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 12, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Aug 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 08, 2024

Major Issues Report

Form 8-K - Current report
Jul 11, 2024

Major Issues Report

Form 8-K - Current report
Jun 20, 2024

Major Issues Report

Form 8-K - Current report
Jun 13, 2024

Major Issues Report

Form 8-K - Current report
May 23, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 23, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 23, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 01, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 30, 2024

Major Issues Report

Form 8-K - Current report
Mar 05, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities